Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study
- PMID: 28431140
- PMCID: PMC5850469
- DOI: 10.1093/rheumatology/kex055
Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study
Erratum in
-
Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.Rheumatology (Oxford). 2023 Nov 2;62(11):3771. doi: 10.1093/rheumatology/kez234. Rheumatology (Oxford). 2023. PMID: 31168593 Free PMC article. No abstract available.
Abstract
Objective: The Patient-Reported Outcomes Measurement Information System (PROMIS)-29 assesses seven health-related quality of life domains plus pain intensity. The objective was to examine PROMIS-29v2 validity and explore clinical associations in patients with SSc.
Methods: English-speaking SSc patients in the Scleroderma Patient-centered Intervention Network Cohort from 26 sites in Canada, the USA and the UK completed the PROMIS-29v2 between July 2014 and November 2015. Enrolling physicians provided medical data. To examine convergent validity, hypotheses on the direction and magnitude of correlations with legacy measures were tested. For clinical associations, t -tests were conducted for dichotomous variables and PROMIS-29v2 domain scores. Effect sizes (ESs) were labelled as small (<0.25), small to moderate (0.25-0.45), moderate (0.46-0.55), moderate to large (0.56-0.75) and large (>0.75).
Results: There were 696 patients (87% female), mean ( s . d .) disease duration 11.6 (8.7) years, 57% with limited cutaneous subtype. Validity indices were consistent with seven of nine hypotheses (| r | =0.51-0.87, P < 0.001), with minor divergence for two hypotheses. Gastrointestinal involvement was associated with significantly worse outcomes for all eight PROMIS-29v2 domains (moderate or moderate to large ES in six of eight). Presence of joint contractures was associated with significant decrements in seven domains (small or small to moderate ESs). Skin thickening, diffuse cutaneous subtype and presence of overlap syndromes were significantly associated (small or small to moderate ESs) with five or six domains.
Conclusion: This study further establishes the validity of the PROMIS-29v2 in SSc and underlines the importance of gastrointestinal symptoms and joint contractures in reduced health-related quality of life.
Keywords: PROMIS; clinical; quality of life; systemic sclerosis; validation.
© The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
References
-
- Seibold J. Scleroderma In: Harris ED, Budd RC, Firestein GS. et al., eds. Kelley's textbook of rheumatology. Vol. 2 7th edn Philadelphia: Elsevier; 2005: 1279–308.
-
- Wigley FM, Hummers LK.. Clinical features of systemic sclerosis In: Hochberg MC, Silman AJ, Smolen JS. et al., eds. Rheumatology. 3rd edn Philadelphia: Mosby; 2003: 1463–80.
-
- Merkel PA, Herlyn K, Martin RW. et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002;46:2410–20. - PubMed
-
- Ntoumazios SK, Voulgari PV, Potsis K. et al. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum 2006;36:173–81. - PubMed
-
- Thombs BD, van Lankveld W, Bassel M. et al. Psychological health and well-being in systemic sclerosis: state of the science and consensus research agenda. Arthritis Care Res 2010;62:1181–9. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases